Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Cetuximab + NKTR-255|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Cetuximab||Erbitux||IMC-C225||EGFR Antibody 39||Erbitux (cetuximab) is a monoclonal antibody directed against EGFR, which inhibits signal transduction and cell proliferation (PMID: 28695301). Erbitux (cetuximab) is FDA approved for use in head and neck squamous cell carcinoma and KRAS wild-type, EGFR positive colorectal cancer (FDA.gov).|
|NKTR-255||NKTR255|NKTR 255||NKTR-255 comprises polymer-conjugated human IL-15, which binds to the IL-15 receptor and acts as an agonist, potentially resulting in enhanced anti-tumor immune response in combination with antibody therapies (Cancer Res July 1 2019 (79) (13 Supplement) 3265).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT04616196||Phase Ib/II||Cetuximab + NKTR-255||A Phase 1b/2 Study of NKTR 255 in Combination With Cetuximab in Solid Tumors||Recruiting||USA||0|